Disclosed is a topical source of hydrogen sulphide for use in the treatment of a nail infection, for example onychomycosis. Also disclosed is a system comprising the topical source of hydrogen sulphide.
A method and system that provides for the automated detection of abnormalities in subject brains from medical imagery of the subject brains, and then applies the known local brain age determination techniques to obtain a local brain age for different image blocks of the subject brain is described. The output from the automatic abnormality detection method and system is used to suppress or negate the output of the local brain age determination method and system, by causing the local brain ages that have been found for image blocks corresponding to subject brain regions for which an abnormality has been detected to be disregarded and/or discarded. Thus, by filtering the output of the local brain age detection method and system with the output of the method and system for automated detection of abnormalities, then only those local brain ages which relate to image blocks of the parts of the subject brain that are more structurally normal are output as local brain ages. Thus, using such a system a clinician can have confidence that the brain age data that is being output is correct, and is not being rendered incorrect by undetected abnormalities in the subject brain.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
A61B 6/00 - Appareils pour diagnostic par radiations, p.ex. combinés avec un équipement de thérapie par radiations
A prosthetic sphincter apparatus comprising: a valve controllable between an open position for allowing a stool to pass through the valve and a closed position for preventing a stool from passing through the valve; and an implant configured to be surgically attached to a body part and to lock the valve inside the implant, wherein the valve is configured to be controllable between the open position and the closed position while remaining locked inside the implant.
The invention provides lateral flow membranes, lateral flow devices, and methods of producing lateral flow membranes. Exemplary lateral flow membranes include a fluid flow path, wherein the fluid flow path includes a detection zone and one or more regions of higher density than another region of the fluid flow path, wherein the one or more regions of higher density extend across the entire thickness of the lateral flow membrane, and wherein the one or more regions of higher density are at least located within and/or adjacent to the detection zone.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
5.
DEVICE AND METHOD FOR 3D REAL-TIME MEDICAL INSTRUMENT TRACKING
A method and a magnetic resonance tomography unit for tracking a medical instrument are disclosed. In the method, a tracking volume is defined enclosing a predefined trajectory of the medical instrument. Two-dimensional (2D) projection images of the tracking volume in presence of the medical instrument are acquired with the magnetic resonance tomography unit from two different view angles. Reference 2D images for the two view angles are determined and a background of the 2D projection images is suppressed. Two sets of 2D coordinates of the medical instrument are extracted from the two 2D projection images and combined to a 3D coordinate set and output on a display.
A61B 34/20 - Systèmes de navigation chirurgicale; Dispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p.ex. pour la stéréotaxie sans cadre
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/56 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
This invention relates to a novel human cell type, namely a human regulatory innate lymphoid cell (ILCreg). The invention provides a human ILCreg. The invention also provides an in vitro population of human ILCregs, pharmaceutical compositions and uses thereof.
A method for calibrating pixel sensitivity for pixels of a hyperspectral image sensor, wherein the hyperspectral image sensor is configured to capture image data, the image data including spectral intensities measured within a plurality of spectral bands, and wherein the method comprises the steps of: providing a reference object; moving the reference object and hyperspectral image sensor relative to each other; capturing a plurality of reference images within a field of view of the hyperspectral image sensor, such that in each reference image the reference object covers a different partial portion of the field of view; selecting a plurality of pixel locations from the field of view; generating a composite reference; and calibrating the pixel sensitivity of the pixels of the hyperspectral image sensor using the composite reference; wherein generating the composite reference comprises, for each of the plurality of pixel locations: selecting, from each image in the plurality of images, image data corresponding to the pixel location; generating, from the selected image data, an intensity profile for the pixel location; and identifying within the intensity profile a segment corresponding to the reference object being observed at the pixel location; and combining the selected segments.
G06T 7/80 - Analyse des images capturées pour déterminer les paramètres de caméra intrinsèques ou extrinsèques, c. à d. étalonnage de caméra
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
A61B 1/313 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments pour l'introduction dans des incisions chirurgicales, p.ex. laparoscopes
9.
ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM
Disclosed herein are synthetic leathers. artificial epidermal layers. artificial dermal layers, layered structures. products produced therefrom and methods of producing the same.
This invention relates to compositions comprising keratins, to methods of producing such compositions and to their use in various therapeutic applications, particularly in dentistry and bone repair. In particular, it relates to keratin compositions produced by dissolving keratins in a solvent, casting the resulting solution and allowing it to dry.
The present disclosure provides a nuclear magnetic resonance (NMR) imaging method, comprising at least one or more of: generating, via a first NMR simulation, an idealised target image assuming substantially idealised NMR scanner performance, and using an initial set of idealised NMR scanner control inputs (x); applying the idealised control inputs to an MR scanner system response model to obtain a set of predicted realised responses (B) representative of MR scanner operating parameters; generating, via a second NMR simulation, a predicted image using the set of predicted realised responses (B); and adapting the initial set of idealised NMR scanner control inputs (x) to give an optimised set of scanner control inputs in dependence on minimisation of a loss function that receives as inputs thereto at least the idealised target image and the predicted image and minimises errors therebetween.
Aspects and embodiments relate to imaging data processing methods, apparatus to process imaging data and computer program products configured to perform such image data processing methods. One aspect provides an apparatus comprising: at least one processor; and at least one memory storing instruction which, when executed by the at least one processor, cause the apparatus at least to: acquire measurement data relating to a feature of interest from imaging data representative of a three- dimensional object comprising the feature of interest; model measurement data distribution as a superposition of: a truth distribution of imprecise measurement of the feature of interest, and a noise distribution; assume a first shape for the truth distribution and a second shape for the noise distribution; and estimate a probability distribution of a measurement of the feature of interest based on the modelled measurement data. Arrangements described herein provide a method of using or processing imaging data collected in relation to a 3-dimensional object including one or more features or elements of interest in such a way that an indication of a representative "true" value of a dimension associated with the feature or element of interest can be determined.
G06F 18/2415 - Techniques de classification relatives au modèle de classification, p.ex. approches paramétriques ou non paramétriques basées sur des modèles paramétriques ou probabilistes, p.ex. basées sur un rapport de vraisemblance ou un taux de faux positifs par rapport à un taux de faux négatifs
G06F 18/2433 - Perspective d'une seule classe, p.ex. une classification "une contre toutes"; Détection de nouveauté; Détection de valeurs aberrantes
13.
COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF DISORDERS AFFECTING THE CENTRAL NERVOUS SYSTEM
Described herein are methods for treating a subject having or at risk of developing a disorder affecting the central nervous system (CNS) (e.g., a neurocognitive disorder, a neuromuscular disorder, or a neurodegenerative disorder (such as FTD, AD, PD, dementia with Lewy bodies, ALS, or a related neurocognitive or motor neuron disorder) or a lysosomal storage disorder). The methods of the disclosure may include administering an adeno-associated viral (AAV) vector that expresses a therapeutic protein (e.g., whose deficiency or lack of activity is associated with the disorder or whose supplementation is likely to benefit the patient). The AAV vectors of the disclosure may be administered, e.g., in particular quantities and by way of particular routes of administration that achieve gene expression in the CNS while avoiding transduction in peripheral tissues (e.g., liver, lung, and spleen).
A61K 38/18 - Facteurs de croissance; Régulateurs de croissance
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
14.
LOW DOSE HUMAN INTERLEUKIN-2 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES (France)
HUMANITAS MIRASOLE SPA (Italie)
The University of Sussex (Royaume‑Uni)
King's College London (Royaume‑Uni)
Queen Mary University of London (Royaume‑Uni)
Sorbonne Universite (France)
Assistance Publique-Hopitaux De Paris (France)
The University of Sheffield (Royaume‑Uni)
Inventeur(s)
Bensimon, Gilbert
Leigh, Peter Nigel
Tree, Timothy
Garlanda, Cecilia
Locati, Massimo
Kirby, Janine
Shaw, Pamela
Malaspina, Andrea
Abrégé
The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to a modified interleukin-15 (IL-15) and a stimulator of interferon genes (STING) agonist and their use in the treatment of inter alia cancer.
Aspects and embodiments provide an apparatus and method to auto-calibrate an eye tracking system for a user. A method in accordance with aspects and embodiments may comprise: providing a model linking eye data with a gaze position on a display, wherein the model is configured to link user eye feature location and an indication of user head location to a gaze location; acquiring user eye data and transforming the acquired user eye data into local eye image space to obtain an indication of user eye feature location and indication of user head location in centralised eye image space; providing an icon at a known position on the display, the icon being associated with a surrounding collider area and transforming the known position to accord with local eye image space; estimating, based upon the model and the transformed acquired user eye data and the transformed known position, whether a user gaze position falls within the collider area; and if the estimated user gaze position is determined to fall within the collider area, associating the transformed acquired user eye data with the transformed known position and adapting the model linking eye data with gaze position based upon the transformed known position and associated transformed acquired eye data. Use of a local eye space based gaze estimation model can help to support a reduction in large gaze errors caused by dataset variations, which may be of particular use when initialising a gaze tracking system for use by a particular user, thereby allowing a gaze tracking system to support substantially instant effective user interaction without a need for an explicit calibration phase.
Mayo Foundation for Medical Education and Research (USA)
King's College London (Royaume‑Uni)
Inventeur(s)
Brinkman, Benjamin H.
Nasseri, Mona
Attia, Tal Pal
Worrell, Gregory A.
Richardson, Mark P.
Viana, Pedro
Abrégé
Seizure onset can be forecast in subjects from subcutaneous electroencephalography (EEG) data input to a trained machine learning algorithm. A multi-stage training process is used to train the machine learning algorithm. A first stage of the training process is implemented on scalp-recorded EEG data. A second stage of the training process may be implemented on subcutaneously recorded EEG data.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/384 - Appareils d’enregistrement ou d’affichage spécialement adaptés à cet effet
G06N 3/0442 - Réseaux récurrents, p.ex. réseaux de Hopfield caractérisés par la présence de mémoire ou de portes, p.ex. mémoire longue à court terme [LSTM] ou unités récurrentes à porte [GRU]
A computing system for providing a mapping of a physical quantity on a biological tissue includes a data interface configured to obtain data from the physical quantity on different spatial points of the biological tissue. The computing system includes a computation module having: a digitization unit configured to produce a digitized representation of the biological tissue in voxels and/or pixels; a concatenation unit configured to spatially correlate the voxels and/or pixels of the produced digitized representation of the biological tissue; and a regression unit configured to process the information of the spatially correlated voxels and/or pixels and generate a regression analysis of the physical quantity on the biological tissue. The computing system includes an output data interface configured to, based on the generated regression analysis, provide a mapping of the physical quantity on the biological tissue. A value of the physical quantity is assigned to each voxel and/or pixel.
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
G01R 33/44 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance magnétique nucléaire [RMN]
The present disclosure relates to an eversion robot system and a method of operating an eversion robot system. In particular, it relates to a steerable eversion robot having a steering structure disposed in its lumen, wherein the steering structure is configured to control a direction of growth of the eversion robot. The eversion robot system of the present invention avoids drag to the surrounding environment while still comprising a mechanism for controlling the direction of growth of the eversion robot for navigating a complex environment.
1234561-21-2 33. The present invention also relates to such porphyrins for use as a medicament, in particular for the treatment of proliferative and/or malignant diseases (such as cancer) and for use for treating or inhibiting metastasis and to pharmaceutical compositions containing such porphyrins.
C07F 9/6524 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle comportant au moins quatre atomes d'azote comme uniques hétéro-atomes du cycle
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
Provided herein is a method of sorting human dermal fibroblasts, comprising (a) providing a cell population comprising human dermal fibroblasts; and (b) separating the human dermal fibroblasts into subpopulations based on expression of one or more cell-surface markers selected from CD39, CD36 and CD26. Also provided are isolated populations of human dermal papillary fibroblasts and cosmetic and therapeutic uses thereof.
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
A61K 35/36 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées Épiderme; Cellules épithéliales; Kératinocytes; Cellules de Langerhans; Cellules ectodermiques
The present invention relates to a regulatory T-cell (Treg) genetically engineered to express a non-activating site-targeting receptor or ligand and a reduced expression level of FAS. Also provided are polynucleotides, vectors, pharmaceutical compositions, methods of genetically engineering the Treg and methods of treatment or prevention of a disease.
The present disclosure relates to new surgical phase recognition methods named LoViT and SKiT. LoViT adopts video-clip level supervision to train a rich spatial feature extractor and then uses the Multi-scale temporal feature aggregator to combine local fine-grained and global macroscopic information to recognise surgical phases. Specifically, the Transformer-based LoViT allows detection and labelling of surgical phases in long video feeds with less loss of information than other existing methods. SKiT adopts video-clip level supervision to train a rich spatial feature extractor and then uses a Key-recorder to extract global macroscopic information indicative to key frames of surgical phase transition. Local fine-grained information and global macroscopic key features are fused using a fusion head. Moreover, our LoViT and SKiT systems utilise a Gaussian Kernal heatmap to learn phase transitions, which is significant to predict and grab the relationship between phases.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 20/40 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène dans le contenu vidéo
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
The present invention provides a robotic locomotive device that is capable of driving itself forwards and backwards, anchoring and steering itself whilst inside a tubular structure, for example, the human colon, or any structure comprising two opposing walls. In this respect, the device is made up of two or three segments covered in an elastic material and driven by an internal actuating mechanism. All of the segments have a concertina configuration that enable a shortening and lengthening motion. As well as contracting and extending in length, at least one of the end segments is capable of bending at an angle away from the longitudinal axis such that it becomes wedged or jammed between the walls of the tubular structure. That is, the end segments are capable of both a bending action and a contracting and extending action. The device moves by alternately jamming a segment between the walls of the tubular structure, and then contracting or extending the segments to inch the device forward with a more effective locomotive action. As such, the present invention provides a simplified design that is more robust to harsh or unclean environments, whilst still maintaining the level of performance required from such a device.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
A61B 1/31 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments pour le rectum, p.ex. proctoscopes, sigmoïdoscopes
The disclosure features compositions and methods for the treatment of disorders associated with expression of wild-type or mutant chromosome 9 open reading frame 72 (C9ORF72) RNA transcripts, that can lead to a pathological phenotype. Disclosed herein are inhibitory RNA constructs that suppress the expression of C9ORF72, as well as viral vectors, such as adeno-associated viral vectors, encoding such inhibitory RNA molecules.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Secretary of State for Health and Social Care (Royaume‑Uni)
Inventeur(s)
Rahman, Khondaker Mirazur
Chen, Yiyuan
Sutton, John Mark
Hind, Charlotte
Abrégé
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof:
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof:
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof:
wherein R1, R2, Q1, Q2, L1 and n are as defined herein. The compounds have antifungal properties and are useful in the treatment of fungal infections, including infections that are resistant to conventions anti-fungal agents.
A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A computer-implemented method of determining one or more target sites usable for treatment of ventricular tachycardia is proposed including receiving three-dimensional model data indicative of a cardiac model modelling an anatomy of a heart of a subject with fibrosis, wherein the cardiac model includes at least one myocardial segment associated with and/or modelled as electrically conducting myocardial tissue and at least one fibrotic segment associated with and/or modelled as insulating fibrotic tissue, simulating the evolution of a cardiac activation wave across the at least one myocardial segment and the at least one fibrotic segment, and determining at least one split location, at which an isosurface of the simulated wave is split into two or more sections, the at least one split location being indicative of a location for the simulated wave hitting a boundary between the at least one fibrotic segment and the at least one myocardial segment.
The present invention discloses a set of human microRNAs, or a primary transcript for such microRNAs, or a precursor of such microRNAs, or a mimic of such microRNAs or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening microRNAs and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
An immunoresponsive cell, such as a T-cell expressing
a second generation chimeric antigen receptor comprising:
(a) a signalling region;
(b) a co-stimulatory signalling region;
(c) a transmembrane domain; and
(d) a binding element that specifically interacts with a first epitope on a target antigen; and
a chimeric costimulatory receptor comprising
(e) a co-stimulatory signalling region which is different to that of (b);
(f) a transmembrane domain; and
g) a binding element that specifically interacts with a second epitope on a target antigen.
An immunoresponsive cell, such as a T-cell expressing
a second generation chimeric antigen receptor comprising:
(a) a signalling region;
(b) a co-stimulatory signalling region;
(c) a transmembrane domain; and
(d) a binding element that specifically interacts with a first epitope on a target antigen; and
a chimeric costimulatory receptor comprising
(e) a co-stimulatory signalling region which is different to that of (b);
(f) a transmembrane domain; and
g) a binding element that specifically interacts with a second epitope on a target antigen.
This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.
This invention relates to a coolant for cooling a device for use in dentistry, the coolant comprising a Newtonian fluid having a viscosity greater than water. The invention also relates to a method of cooling a device for use in dentistry utilising the coolant, the coolant for use in a method of cooling a device for use in dentistry and an apparatus and kit comprising the coolant.
This invention relates to a tip for a vibrating scaler for use in dentistry, the tip comprising a proximal inlet for receiving coolant; a distal working portion for being vibrated to aid scaling; and an outlet for delivering coolant received via the inlet to cool the working portion, wherein the working portion defines a concave side and a convex side of the tip and the outlet is located on the convex side of the tip. The invention also relates to a vibrating scaler for use in dentistry that comprises the tip.
The disclosure features compositions and methods for the treatment of disorders associated with expression of wild-type or mutant superoxide dismutase 1 (SOD1) RNA transcripts, that can lead to a pathological phenotype. Disclosed herein are inhibitory RNA constructs that suppress the expression of SOD1, as well as viral vectors, such as adeno-associated viral vectors, encoding such inhibitory RNA molecules.
In one aspect, the present invention relates to an anti-folate receptor alpha (FRα) immunoglobulin E (IgE) antibody for use in treating a low FRα-expressing tumor in a subject.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
35.
LOW DOSE HUMAN INTERLEUKIN-2 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS IN A SUBGROUP OF PATIENTS
CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES (France)
THE UNIVERSITY OF SUSSEX (Royaume‑Uni)
HUMANITAS MIRASOLE SPA (Italie)
KING'S COLLEGE LONDON (Royaume‑Uni)
THE UNIVERSITY OF SHEFFIELD (Royaume‑Uni)
QUEEN MARY UNIVERSITY OF LONDON (Royaume‑Uni)
Inventeur(s)
Bensimon, Gilbert
Leigh, Peter Nigel
Tree, Timothy
Al-Chalabi, Ammar
Garlanda, Cecilia
Locati, Massimo
Kirby, Janine
Shaw, Pamela
Malaspina, Andrea
Abrégé
The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1 x106to 3x106 international units (IU) and the subject has a low to medium concentration of p-NFH in cerebrospinal fluid (CSF p-NFH) or a low to medium concentration of NFL or NFM in cerebrospinal fluid, blood, serum or plasma before human IL-2 administration. The invention also relates to medical uses where the CSF p-NFH or CSF, blood, serum or plasma NFL or NFM concentration is used to select the best administration scheme or as a biomarker for stratified randomization of a cohort of ALS patients in the context of a clinical trial assessing the therapeutic efficiency of a candidate ALS treatment.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61P 27/00 - Médicaments pour traiter les troubles des sens
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
The invention provides constructs, pharmaceutical compositions, methods of preparing a ferritin nanocage, ferritin nanocages, methods of treating or preventing a disease in a subject, and methods of raising an immune response against an antigen. Exemplary constructs include two ferritin subunits connected by a linker, wherein the linker includes a cleavage site, wherein the linker is arranged to prevent the ferritin subunits from self-assembling into a ferritin nanocage, and wherein cleavage of the linker at the cleavage site does not prevent the ferritin subunits from self-assembling into a ferritin nanocage.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The present disclosure relates to a method for automated characterisation of images obtained using a medical imaging modality, in particular, the present disclosure relates to a method for analysis of cine cardiac magnetic resonance (CMR) images using an artificial intelligence (AI) framework.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
42.
ANATOMICAL AND FUNCTIONAL ASSESSMENT OF CAD USING MACHINE LEARNING
Anatomical and functional assessment of coronary artery disease (CAD) using machine learning and computational modeling techniques deploying methodologies for non-invasive Fractional Flow Reserve (FFR) quantification based on angiographically derived anatomy and hemodynamics data, relying on machine learning algorithms for image segmentation and flow assessment, and relying on accurate physics-based computational fluid dynamics (CFD) simulation for computation of the FFR.
The invention features compositions and methods useful in treating inflammation of the gut, such as inflammation associated with inflammatory bowel disease, by modulating γδ T cells (e.g., Vγ4+ cells). Particular embodiments include Vγ4+ cells expressing heterologous protein; polynucleotides containing genes contributing to functional expression of BTNL3, BTNL8, and HNF4A; methods of treating a subject using Vγ4+ cells or gene therapy; and methods of identifying a subject having imitations associated with inflammation of the gut. Compositions and methods of the invention can be used in the treatment of inflammation and cancer of the gut.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
PHARMACEUTICAL COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF A CONDITION ASSOCIATED WITH A REDUCTION IN THE NUMBER OF LACTOBACILLI IN THE VAGINA
The present invention provides a pharmaceutical composition for use in the prevention or treatment of a condition associated with a reduction in the number of Lactobacilli in the vagina of a subject relative to a healthy subject, wherein the composition comprises from 1.3 to 1.7 w/v % glycogen and less than 0.1 w/v % lactic acid.
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The invention features compositions and methods useful in treating inflammation of the gut, such as inflammation associated with inflammatory bowel disease, by modulating γδ T cells (e.g., Vγ4+ cells). Particular embodiments include Vγ4+ cells expressing heterologous protein; polynucleotides containing genes contributing to functional expression of BTNL3, BTNL8, and HNF4A; methods of treating a subject using Vγ4+ cells or gene therapy; and methods of identifying a subject having imitations associated with inflammation of the gut. Compositions and methods of the invention can be used in the treatment of inflammation and cancer of the gut.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
47.
VITAMIN D3 PHOSPHATE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHODS FOR PREPARING THE COMPOUND
Disclosed is the compound vitamin D3 phosphate and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compound and methods for preparing the compound. Also disclosed are methods of treating vitamin D deficiency using the compound. The compound is particularly suitable for transdermal delivery.
This invention relates to methods of making immunoresponsive cells, immunoresponsive cells thereof, pharmaceutical compositions, kits, uses thereof and methods of treatment. In particular, there is provided a method of making an immunoresponsive cell, wherein the method comprises (a) genetically modifying an immune cell to express an NKG2D polypeptide; wherein the immune cell has been activated with anti-CD3 and anti-CD28 antibodies, or fragments thereof, conjugated to a nanomatrix; or (b) activating an immune cell, wherein the immune cell has been genetically modified to express an NKG2D polypeptide and wherein activation is with anti-CD3 and anti-CD28 antibodies, or fragments thereof, conjugated to a nanomatrix.
An immunoresponsive cell, such as a T-cell expressing
(i) a second generation chimeric antigen receptor comprising:
(a) a signalling region;
(b) a co-stimulatory signalling region;
(c) a transmembrane domain; and
(d) a binding element that specifically interacts with a first epitope on a target antigen; and
(ii) a chimeric costimulatory receptor comprising
(e) a co-stimulatory signalling region which is different to that of (b);
(f) a transmembrane domain; and
g) a binding element that specifically interacts with a second epitope on a target antigen.
An immunoresponsive cell, such as a T-cell expressing
(i) a second generation chimeric antigen receptor comprising:
(a) a signalling region;
(b) a co-stimulatory signalling region;
(c) a transmembrane domain; and
(d) a binding element that specifically interacts with a first epitope on a target antigen; and
(ii) a chimeric costimulatory receptor comprising
(e) a co-stimulatory signalling region which is different to that of (b);
(f) a transmembrane domain; and
g) a binding element that specifically interacts with a second epitope on a target antigen.
This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.
Provided herein is method of treating a skin condition in a subject, comprising isolating cells comprising primary dermal fibroblasts from a skin sample obtained from the subject, and administering the freshly-isolated cells to skin of the subject. Also provided are freshly isolated cell preparations comprising primary dermal fibroblasts and uses thereof.
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
Centre National de la Recherche Scientifique (CNRS) (France)
Institut National de La Sante et de la Recherche Medicale (INSERM) (France)
King's College London (Royaume‑Uni)
Department of Health and Human Services (USA)
UNIV PARIS XIII PARIS-NORD VILLETANEUSE (France)
Universite de Paris (France)
Inventeur(s)
Annio, Giacomo
Müller-Reinwald, Verena
Sinkus, Ralph
Darwish, Omar
Schnell, Wilfried
Falkner, Tamara Elisabeth
Gharib, Ahmed M.
Abrégé
The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/563 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p.ex. angiographie à écoulement contrasté
52.
Engineered skin equivalent, method of manufacture thereof and products derived therefrom
Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same.
The invention provides methods of optically detecting an analyte in a medium as the analyte moves with respect to a nanopore. The analyte may be, for example, a biological molecule such as a polynucleotide or polypeptide. Systems and apparatuses for carrying our such methods are also provided.
This invention relates to a method for expanding immune cells, the method comprising co-culturing the immune cells and at least one epithelial organoid, wherein the epithelial organoid comprises more epithelial cells than mesenchymal cells. Also provided are immune cells obtainable by the method, an in vitro population of innate lymphoid cells (ILCs) comprising at least 5 x 103 ILCs, pharmaceutical compositions and uses thereof.
A modified U7 snRNA construct comprising at least one antisense sequence having between 16 to 30 nucleotides which are at least 90% complementary to a splicing element of a TDP- 43 regulated cryptic exon sequence or flanking regions thereof and wherein the U7 snRNA construct is capable of modulating splicing of the TDP-43 regulated cryptic exon in a cell. The splicing element may be selected from a splice site, a TDP-43 binding region, or an exonic splice enhancer. Vectors and pharmaceutical compositions comprising the construct are also described, as well as constructs for use in the treatment of diseases associated with TDP-43 dysfunction. Example TDP-43 regulated cryptic exon sequences include TDP-43 regulated cryptic exons in UNC13A, STMN2 and INSR genes.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A modified U7 snRNA construct, more particularly a U7 smOPT construct, is described having (i) an antisense sequence having between 16 to 30 nucleotides which is at least 90% complementary to a TDP-43 regulated cryptic exon sequence or flanking regions thereof, and (ii) a sequence comprising a binding domain for a hnRNP protein, wherein the construct is capable of modulating splicing of the TDP-43 regulated cryptic exon in a cell. Vectors and pharmaceutical compositions comprising the construct are also described, as well as constructs for use in the treatment of diseases associated with TDP-43 dysfunction. Example TDP-43 regulated cryptic exon sequences include TDP-43 regulated cryptic exons in UNC13A, STMN2 and INSR genes.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
57.
SATIETY PROMOTING COMPOSITIONS, FOODSTUFFS AND METHODS OF PRODUCTION THEREOF
A dietary composition and methods of producing the same wherein the fibre structure of said composition influences enteroendocrine-mediated appetite regulation. Characterised in that said composition includes intact cells from at least one legume.
There is described a nanoparticle comprising one or more peptides having a sequence comprising the motif GLLxLLxL-LLxAAG, wherein each x is independently selected from arginine (R), histidine (H), lysine (K), aspartic acid (D) or glutamic acid (E). Also described is a pharmaceutically acceptable composition comprising the nanoparticle and one or more pharmaceutically acceptable excipients, for use in the treatment of cancer. In addition, there is described a method of treatment of cancer involving administering the pharmaceutically acceptable composition to a patient with cancer, and a kit for treating or preventing cancer comprising the pharmaceutically acceptable composition.
A method for determining geometry of a face mask comprising a main body and a seal configured to engage a nasal region, cheeks and a chin of a user. The method comprises collecting (402) facial data of the user comprising a point cloud comprising a plurality of points on a skin surface in a nasal region, eye region and chin region of the user; determining (406), based on the facial data, in at least one of the eye region and the chin region of the user, an estimated face size of the user; determining (408), based on the facial data comprising the plurality of points in the nasal region, a best-fit Gaussian curve to a profile of a nose of the user; and using the estimated face size of the user and the determined Gaussian curve to select (410) parameters for a profile geometry of the face mask.
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (Italie)
FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (Espagne)
KING'S COLLEGE LONDON (Royaume‑Uni)
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Tartaglia, Gian Gaetano
Armaos, Alexandros
Cid, Fernando
Sanchez De Groot, Natalia
Grana-Montes, Ricardo
Pastore, Annalisa
Zacco, Elsa
Horrocks, Mathew
Kantelberg, Owen
Abrégé
The invention relates to a short single-stranded DNA or RNA aptamer that is capable of binding the TDP-43 protein and of detecting all of the different TDP-43 structures individually, from the soluble monomer to the TDP-43 larger aggregates. The aptamer of the invention is also capable of inhibiting aggregation of TDP-43. Because of these properties, the RNA aptamer of the invention is suitable for use in both the diagnosis and therapeutic treatment and prevention of TDP-43-related proteinopathies, such as ALS and FTD.
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention relates to a peptide. The peptide can be used in the therapy or prevention of Type 1 Diabetes (T1D), particularly in a patient with a DR3-DQ2 haplotype. The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the peptide, as well as to a method of identifying T1D-relevant antigen drivers, methods of identifying subjects as being at high-risk of T1D and patients as being suitable for and/or responsive to T1D treatment.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
Methods and systems for obtaining biochemical and/or structural information relating to tissues using Raman spectroscopy. Polarised light is directed to tissue using a probe. The light is reflected from the tissue, producing Raman scattering. The Raman scattering is collected by the system and split into two polarised components. The two polarised components are simultaneously imaged using a spectrometer to produce two Raman spectra. The Raman spectra are then processed and analysed using a computer program to obtain biochemical and/or structural information relating to the tissue.
The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
64.
METHODS OF TREATING CANCER USING REPLICATION STRESS MODULATORS
An agent that generates DNA replication stress and/or inhibits pathways involved in DNA replication stress tolerance for use in a method of treating a patient with cancer. The treatment comprises: determining whether the cancer expresses HORMAD1; and, if so, administering to said patient an agent that generates DNA replication stress and/or inhibits pathways involved in DNA replication stress tolerance.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
Aspects and embodiments relate to a body part support, a device comprising a body part support and a method of supporting a body part. More particularly, aspects and embodiments may relate to a medical imaging body part support. The imaging support of various aspects and embodiments comprises an inflatable bladder. Aspects and embodiments provide a body part support comprising: a frame and an inflatable bladder. The frame comprises a cover portion and a base portion. The cover and base portion are reversibly moveable with respect to each other between an open position and a closed position. In the open position the body part is locatable within the base portion. In the closed position the cover portion and base portion are securable together to encircle at least a portion of the body part locatable within the base portion. The inflatable bladder is mountable on the frame, located such that inflation of the inflatable bladder causes a reduction of a gap formed between the interior of the frame and encircled portion of the body part locatable within the base portion. An arrangement in accordance with described aspects mitigates body part movement within the support.
A61B 6/04 - Mise en position des patients; Lits inclinables ou similaires
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
A61B 6/00 - Appareils pour diagnostic par radiations, p.ex. combinés avec un équipement de thérapie par radiations
A61N 5/10 - Radiothérapie; Traitement aux rayons gamma; Traitement par irradiation de particules
A method for expanding a population of γδ T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-β) under conditions in which the production of effector γδ T-cells having therapeutic activity against malignant disease is favored. The use of TGF-β in the production of effector cells in particular Vγ9Vδ2 T-cells is also described and claimed.
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
A dental filling material or precursor thereof for use in therapy, which material comprises lithium and is capable of releasing lithium under physiological conditions.
The present disclosure relates to a method for fabricating an array of nanoprojections, where the nanoprojections may include nanopillars, nanowires, nanoneedles or nanocones. The present disclosure also relates to an array of the nanoprojections, and to uses of such arrays.
A hardware system is provided which includes a neural network. The neural network comprises nodes interconnected by synapses implemented by respective hardware devices. The hardware devices are configured to generate an output by performing an inference operation using the neural network. The operation of the synapses is controlled by setting a physical property of the respective hardware devices implementing the respective synapses, at least one of setting or reading the physical property being subject to noise. The neural network associates probabilistic weight distributions with respective synapses. Setting the physical property of a given synapse comprises applying a weight value sampled from the weight distribution corresponding to that synapse. Performing the inference operation comprises performing multiple inference determinations using multiple respective sampled weight values for the synapses to obtain multiple inference results. The multiple inference results indicate a confidence interval for the output of the inference operation. The use of multiple inference determinations acts further to suppress the effect of noise for at least one of setting or reading the physical property of the synapses. Such a hardware system may also be used for generating and training the neural network.
The present invention relates to cell radiolabelling agents. The invention provides a method of preparing oxine-containing cell radiolabelling agents, a kit for the preparation of oxine-containing cell radiolabelling agents and a formulation for the preparation of oxine-containing cell radiolabelling agents, in particular 89Zr-oxine cell radiolabelling agents.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
Centre National de la Recherche Scientifique (CNRS) (France)
Institut National de La Sante et de la Recherche Medicale (INSERM) (France)
King's College London (Royaume‑Uni)
Department of Health and Human Services (USA)
UNIV PARIS XIII PARIS-NORD VILLETANEUSE (France)
Universite de Paris (France)
Inventeur(s)
Annio, Giacomo
Muller-Reinwald, Verena
Sinkus, Ralph
Darwish, Omar
Schnell, Wilfried
Falkner, Tamara Elisabeth
Gharib, Ahmed M.
Abrégé
The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/563 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p.ex. angiographie à écoulement contrasté
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
The present disclosure relates to a federated learning algorithm utilizing time-triggered global aggregation and user tier systems to group local users with similar computational speeds. In this case at the start of a fixed time period a global model is transmitted to users who completed their local training in the previous time period and ready to perform the next local training. Since users are tiered/grouped based on their computational speeds, users in the same tier should all receive the global model at the same time. The users who have been supplied a global model then complete their local computation. Once local computation is completed, local models are sent to the global server. Intra-tier aggregation then occurs, where local models from the same tier are aggregated together. Once intra-tier aggregation is completed, the aggregated tier models are then used to update the overall global model, by aggregating the intra-tier aggregation models with the global model. Since tiers with faster computational speeds can send and receive models more frequently then tiers with slower computational speeds, the slower computational speed tiers are attributed a higher weighting to ensure that each tier has an equal effect 15 on the global model training independent of computational speed, also referred to herein as computational bias. Furthermore, the time-triggered global aggregation setting is advantageous as faster users do not have to wait for slower users before global aggregation and can continue to process the next set of FL input information that requires processing. Conversely, slower users are not biased out of the FL scheme by virtue of simply being slower the higher weighting applied to the computational results of these users means that they can still impact the whole FL results. A fairer result that addresses some of the problems of asynchronous FL described earlier is therefore obtained. Moreover, the amount of global aggregation triggers is reduced to improve communication efficiency. Also, since users are grouped into small tiers based on their computational speeds, the straggler issue can be alleviated, and the training efficiency can be enhanced compared with synchronous FL.
This invention relates to radiolabelled compounds as described herein, precursor compounds and reference compounds, as well as pharmaceutical compositions comprising the radiolabelled compounds, which are for use in a diagnostic method practised on the human or animal body using positron emission tomography (PET).
C07D 277/66 - Benzothiazoles avec uniquement des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués liés en position 2 avec des cycles ou des systèmes cycliques aromatiques liés directement en position 2
The invention relates to a population of cells, wherein said population of cells comprises at least 50% macrophage or monocyte cells, characterised in that at least 50% of said macrophage or monocyte cells express each of the markers: MRC1; TIE2; and CD163. The invention also relates to uses of those cells, methods of making them and methods of treating a subject by administering them.
A method of visualising the three-dimensional internal surface of a lumen in real-time comprising using various combinations of image, motion and shape data obtained from an endoscope with a trained neural network and a curved lumen model. The three-dimensional internal surface may be unfolded to form a two-dimensional visualisation.
This invention relates to an immunoresponsive cell comprising a chimeric NKG2D protein. The immunoresponsive cell is a T-cell, natural killer (NK) cell, macrophage or neutrophil and the chimeric NKG2D protein comprises a human NKG2D extracellular domain or a variant thereof, and a murine NKG2D transmembrane domain or a variant thereof. The disclosure also relates to isolated polynucleotide(s) encoding the chimeric NKG2D protein and the use of the immunoresponsive cells or isolated polynucleotides in therapy or the treatment of cancer.
This invention relates to a polynucleotide construct comprising (a) an artificial microRNA (amiRNA) coding region comprising a polynucleotide encoding an amiRNA and (b) a protein-coding region comprising a polynucleotide encoding a chimeric antigen receptor (CAR). Also provided are vectors, host cells, pharmaceutical compositions, kits, methods of preparing host cells and uses thereof.
Examples of the present disclosure include a method and system for deriving a computer implemented trained artificial intelligence (AI) model that is capable of predicting arterial input function (AIF) from blood and myocardial signal intensity curves of a subject obtained using a magnetic resonance (MR) scanner during injection of a single high dosage bolus of contrast agent that would otherwise cause signal saturation. The method and system requires an input data set of a large number of prior obtained dual bolus or dual sequence sets of scan measurements to be used as training data for the AI model. Once the computer implemented trained AI model has been obtained, it is deployed in a further method and system which receives MR data for a particular subject for which myocardial perfusion parameters such as the AIF is to found, the MR data being obtained from an MR scan taken during injection of a single bolus of contrast agent at a concentration sufficient to give MR signal saturation. The trained AI model is then able to predict,?
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition
80.
EXPANSION OF GAMMA DELTA T CELLS, COMPOSITIONS, AND METHODS OF USE THEREOF
The present invention provides methods of expanding γδ T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded γδ T cells and methods of using the expanded γδ T cells (e.g., a part of an adoptive T cell therapy).
The present invention relates to chimeric receptors (e.g. CARs including both single chain and multichain CARs) that bind to TREM2 ligands and their use in therapy. In particular, the invention provides a chimeric receptor comprising:
(a) an exodomain comprising the ligand binding domain of TREM2 or a functional variant thereof, optionally wherein said exodomain is resistant to cleavage by a sheddase;
(b) a transmembrane domain; and
(c) an endodomain comprising an intracellular signalling domain.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
H04B 10/50 - Systèmes de transmission utilisant des ondes électromagnétiques autres que les ondes hertziennes, p.ex. les infrarouges, la lumière visible ou ultraviolette, ou utilisant des radiations corpusculaires, p.ex. les communications quantiques Émetteurs
A61F 9/008 - Procédés ou dispositifs pour la chirurgie de l'œil utilisant un laser
This invention relates to an immune cell which is genetically engineered to express an exogenous alternative carbon source (ACS) metabolism gene, wherein the ACS is not glucose and wherein the ability of the immune cell to metabolise the ACS is increased due to expression of the exogenous ACS metabolism gene. Also provided are polynucleotides, vectors, pharmaceutical compositions, methods of genetically engineering the immune cell and methods of use in therapy.
A prosthetic sphincter apparatus comprising: a valve controllable between an open position for allowing a stool to pass through the valve and a closed position for preventing a stool from passing through the valve; and an implant configured to be surgically attached to a body part and to lock the valve inside the implant, wherein the valve is configured to be controllable between the open position and the closed position while remaining locked inside the implant.
A device for improved photo-curing of an RBC by spectrally blending light for use in dental treatments such as fillings. The device comprises a base plate, a rotating mechanism, and a light source assembly, wherein the light source assembly consists of a plurality of LEDs. Further, in some embodiments, the plurality of LEDs comprising the light source assembly have differing wavelength emission ranges and peaks. In other embodiments, the invention has a light source module consisting of a plurality of LEDs with the same wavelength emissions peaks. The light source assembly or light source module is fixed to the base plate and the base plate is fixed to the rotating mechanism. The base plate and light source assembly or light source module synchronously rotate. With the light source assembly, this results in spectrally blending the differing emissions spectrums within the light source assembly and subsequently causing better photo- polymerization of the RBC. With the light source module, this results in blending of the irradiation which reduces spotlighting and causes more consistent photo-polymerization of the RBC.
Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same.
In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention provides an engineered regulatory T cell (Treg) comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen recognition domain which specifically binds to asialoglycoprotein receptor (ASGR). The present invention also provides a method of promoting liver tissue repair and/or regeneration in a subject which comprises the step of administering to the subject an engineered Treg comprising a CAR or a pharmaceutical composition comprising the engineered Treg, wherein the CAR comprises a liver-specific antigen recognition domain.
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A system and method for estimating LV filling pressure of the heart of a human patient are disclosed. The system comprises: a data processing apparatus; an imaging system for non-invasively obtaining images of the patient's heart and for providing imaging data to the data processing apparatus; and a data input device for receiving patient specific parameters relating to BMI and systolic arterial blood pressure of the patient and for providing the patient specific parameters to the data processing apparatus. The data processing apparatus is configured to perform the method as follows: (a) use the imaging data to obtain cardiac markers including an estimate of LA reservoir strain and an estimate of the time constant of LV isovolumic pressure decay, and use the patient specific parameters directly or to determine additional cardiac markers including systolic pressure and BMI; (b) determine an estimate of the minimum LV diastolic pressure as a summation of a value derived from each of the cardiac markers multiplied by a corresponding constant of proportionality and added to a constant value, wherein the constant value and the various constants of proportionality have been derived from a statistical analysis of historic patient data for a plurality of patients; (c) estimate the peak pressure drop during early diastole between left atrium and left ventricle and hence obtaining a maximum difference between the LA pressure and LV pressure; and (d) calculate an estimate of LV filling pressure as the sum of values from step (b) and step (c) above.
Examples of the present disclosure relate to an apparatus comprising input circuitry configured to acquire imaging data corresponding to a branched organic structure, and image processing circuitry. The image processing circuitry is configured to determine, from the imaging data, a parametric configuration of the branched organic structure comprising solid and volumetric scaffolding data indicative of the branched organic structure, and determine, based on the scaffolding data, a multi-dimensional parametric representation of the branched organic structure.
A broadcasting vehicular ad-hoc network in an intelligent transportation system includes the provision of a vehicle capable of sensing attributes of the network even whilst transmitting packets on that network. Beneficially, a listen-whilst-transmit system allows collisions and network congestion to be detected even when a vehicle is transmitting. Based on this knowledge, the vehicle may abort transmission, modify its retransmission process, and enable prioritisation of retransmission between multiple vehicles in dependence on numerous factors, including the operating autonomous level of the different vehicles in the network. The system may further implement a system in which both periodic and aperiodic packets are transmitted in a vehicular ad-hoc network.
H04W 4/46 - Services spécialement adaptés à des environnements, à des situations ou à des fins spécifiques pour les véhicules, p.ex. communication véhicule-piétons pour la communication de véhicule à véhicule
H04W 84/18 - Réseaux auto-organisés, p.ex. réseaux ad hoc ou réseaux de détection
H04L 5/14 - Fonctionnement à double voie utilisant le même type de signal, c. à d. duplex
CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES (France)
HUMANITAS MIRASOLE SPA (Italie)
THE UNIVERSITY OF SUSSEX (Royaume‑Uni)
KING'S COLLEGE LONDON (Royaume‑Uni)
QUEEN MARY UNIVERSITY OF LONDON (Royaume‑Uni)
SORBONNE UNIVERSITE (France)
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (France)
THE UNIVERSITY OF SHEFFIELD (Royaume‑Uni)
Inventeur(s)
Bensimon, Gilbert
Leigh, Peter Nigel
Tree, Timothy
Garlanda, Cecilia
Locati, Massimo
Kirby, Janine
Shaw, Pamela
Malaspina, Andrea
Abrégé
The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU) Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 HI human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
93.
Graph-based Hemodynamics for Biomarkers of Neurovascular Resilience
Examples of the present disclosure relate to an apparatus comprising input circuitry configured to acquire imaging data corresponding to a branched biological structure. The apparatus further comprises image processing circuitry configured to: extract, from the imaging data, a configuration of the branched biological structure; determine graph data indicative of the configuration of the branched biological structure; and detect, based on the graph data, a biological characteristic of the branched biological structure.
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
G06T 7/174 - Découpage; Détection de bords impliquant l'utilisation de plusieurs images
Aspects and embodiments relate to a plasmonic metamaterial structure, applications and devices including that plasmonic metamaterial structure, and a method of forming that plasmonic metamaterial structure. Aspects and embodiments provide a plasmonic metamaterial structure which comprises: a plurality of optical antenna elements. The plurality of optical antenna elements comprise: a first electrode, a second electrode and a plasmonic nanostructure element located between the first and second electrode to form an electron tunnelling junction between the first and second electrodes. The plurality of optical antenna elements are configured such that the electromagnetic field of one optical antenna element spatially overlaps that of adjacent optical antenna elements and adjacent optical antenna elements are electromagnetically coupled to allow the plurality of optical antenna elements to act as a plasmonic metamaterial. Aspects and embodiments also provide devices including that plasmonic metamaterial structure, and a method of forming that plasmonic metamaterial structure. Aspects and embodiments recognise that the sensitivity of an electron tunnelling junction, coupled with provision of a plurality of optical antenna elements may provide a practical structure which can provide sensing platforms, modulation, light source and nanoscale light source devices and applications.
H01Q 15/00 - Dispositifs pour la réflexion, la réfraction, la diffraction ou la polarisation des ondes rayonnées par une antenne, p.ex. dispositifs quasi optiques
Described herein are microRNA expression systems, and/or microRNA cloning systems. Described herein are also methods of expressing microRNAs or guide sequences against target mRNA, methods of producing said microRNA cloning systems and methods of knocking down target polynucleotides, such as mRNA.
Described herein are microRNA expression systems, and/or microRNA cloning systems. Described herein are also methods of expressing microRNAs or guide sequences against target mRNA, methods of producing said microRNA cloning systems and methods of knocking down target polynucleotides, such as mRNA.
Disclosed is a patch or bandage for tissue regeneration and/or repair. The bandage comprises i) one or more proteins from the Wnt family, or an agonist of the Wnt signalling pathway; and ii) a scaffold, wherein the one or more Wnt proteins or Wnt agonist is immobilised on the scaffold, and wherein the scaffold is formed from a functionalised biocompatible polymer.
A computer-implemented method of determining one or more target sites (200) usable for treatment of ventricular tachycardia is proposed. The method comprises receiving, with a computing device (100) including one or more processors (110), three-dimensional model data indicative of a cardiac model (150) modelling an anatomy of a heart of a subject with fibrosis, wherein the cardiac model (150) includes at least one myocardial segment (160) associated with and/or modelled as electrically conducting myocardial tissue and at least one fibrotic segment (170) associated with and/or modelled as insulating fibrotic tissue. The method further comprises simulating (S1) the evolution of a cardiac activation wave across the at least one myocardial segment (160) and the at least one fibrotic segment (170), and determining (S2) at least one split location (182), at which an isosurface (180) of the simulated wave is split into two or more sections (18a-c), the at least one split location (182) being indicative of a location for the simulated wave hitting a boundary between the at least one fibrotic segment (170) and the at least one myocardial segment (160). The method further comprises determining one or more target sites (200) based on the determined at least one split location (182).
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61B 5/367 - Modalités électriques se rapportant au cœur, p.ex. électrocardiographie [ECG] Études électrophysiologiques [EEP], p.ex. cartographie de l’activation électrique ou cartographie électroanatomique
SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE (Royaume‑Uni)
Inventeur(s)
Sutton, John Mark
Mason, Andrew James
Amison, Richard Thomas
Abrégé
The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/46 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés
Described herein are methods for treating a subject having or at risk of developing a disorder affecting the central nervous system (CNS) (e.g., a neurocognitive disorder, a neuromuscular disorder, or a neurodegenerative disorder (such as FTD, AD, PD, dementia with Lewy bodies, ALS, or a related neurocognitive or motor neuron disorder) or a lysosomal storage disorder). The methods of the disclosure may include administering an adeno-associated viral (AAV) vector that expresses a therapeutic protein (e.g., whose deficiency or lack of activity is associated with the disorder or whose supplementation is likely to benefit the patient). The AAV vectors of the disclosure may be administered, e.g., in particular quantities and by way of particular routes of administration that achieve gene expression in the CNS while avoiding transduction in peripheral tissues (e.g., liver, lung, and spleen).
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
